CN111297918A - Composition of EGCG and cordyceps militaris extract and preparation method and application thereof - Google Patents
Composition of EGCG and cordyceps militaris extract and preparation method and application thereof Download PDFInfo
- Publication number
- CN111297918A CN111297918A CN202010369198.6A CN202010369198A CN111297918A CN 111297918 A CN111297918 A CN 111297918A CN 202010369198 A CN202010369198 A CN 202010369198A CN 111297918 A CN111297918 A CN 111297918A
- Authority
- CN
- China
- Prior art keywords
- egcg
- cordyceps militaris
- resisting
- extract
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical group O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 title claims abstract description 102
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 title claims abstract description 102
- 241001264174 Cordyceps militaris Species 0.000 title claims abstract description 89
- 239000000284 extract Substances 0.000 title claims abstract description 62
- 239000000203 mixture Substances 0.000 title claims abstract description 23
- 238000002360 preparation method Methods 0.000 title claims description 44
- 238000000605 extraction Methods 0.000 title description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 22
- 238000002156 mixing Methods 0.000 claims abstract description 19
- 238000001035 drying Methods 0.000 claims abstract description 9
- 238000003756 stirring Methods 0.000 claims abstract description 9
- 230000036039 immunity Effects 0.000 claims abstract description 7
- 230000001105 regulatory effect Effects 0.000 claims abstract description 7
- 206010061218 Inflammation Diseases 0.000 claims abstract description 6
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 6
- 241000700605 Viruses Species 0.000 claims abstract description 6
- 230000004054 inflammatory process Effects 0.000 claims abstract description 6
- 206010003210 Arteriosclerosis Diseases 0.000 claims abstract description 5
- 241000894006 Bacteria Species 0.000 claims abstract description 5
- 208000007536 Thrombosis Diseases 0.000 claims abstract description 5
- 208000011775 arteriosclerosis disease Diseases 0.000 claims abstract description 5
- 230000002526 effect on cardiovascular system Effects 0.000 claims abstract description 5
- 238000001704 evaporation Methods 0.000 claims abstract description 5
- 210000000653 nervous system Anatomy 0.000 claims abstract description 5
- 230000003647 oxidation Effects 0.000 claims abstract description 5
- 238000007254 oxidation reaction Methods 0.000 claims abstract description 5
- 230000036542 oxidative stress Effects 0.000 claims abstract description 5
- 150000003254 radicals Chemical class 0.000 claims abstract description 5
- 239000007962 solid dispersion Substances 0.000 claims description 54
- 239000000706 filtrate Substances 0.000 claims description 16
- 239000008187 granular material Substances 0.000 claims description 16
- 239000007787 solid Substances 0.000 claims description 14
- 239000002775 capsule Substances 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 229940107187 fructooligosaccharide Drugs 0.000 claims description 7
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims description 7
- 238000004140 cleaning Methods 0.000 claims description 4
- 239000012141 concentrate Substances 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 239000012535 impurity Substances 0.000 claims description 4
- 238000002386 leaching Methods 0.000 claims description 4
- 238000010298 pulverizing process Methods 0.000 claims description 4
- 210000004204 blood vessel Anatomy 0.000 claims description 3
- 206010020718 hyperplasia Diseases 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 238000007873 sieving Methods 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 238000005550 wet granulation Methods 0.000 claims description 3
- 230000000144 pharmacologic effect Effects 0.000 abstract description 6
- 230000002195 synergetic effect Effects 0.000 abstract description 6
- 125000004185 ester group Chemical group 0.000 abstract description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract description 3
- 238000005411 Van der Waals force Methods 0.000 abstract description 2
- 239000000843 powder Substances 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- -1 nitrogen glycoside Chemical class 0.000 description 8
- 238000001514 detection method Methods 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 239000003937 drug carrier Substances 0.000 description 7
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 239000005715 Fructose Substances 0.000 description 5
- 229930091371 Fructose Natural products 0.000 description 5
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- OFEZSBMBBKLLBJ-UHFFFAOYSA-N cordycepine Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)CC1O OFEZSBMBBKLLBJ-UHFFFAOYSA-N 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 239000004375 Dextrin Substances 0.000 description 4
- 229920001353 Dextrin Polymers 0.000 description 4
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 4
- 239000004698 Polyethylene Substances 0.000 description 4
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 4
- 235000019425 dextrin Nutrition 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 4
- 229920000573 polyethylene Polymers 0.000 description 4
- 238000013268 sustained release Methods 0.000 description 4
- 239000012730 sustained-release form Substances 0.000 description 4
- 239000000811 xylitol Substances 0.000 description 4
- 235000010447 xylitol Nutrition 0.000 description 4
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 4
- 229960002675 xylitol Drugs 0.000 description 4
- KQLDDLUWUFBQHP-UHFFFAOYSA-N Cordycepin Natural products C1=NC=2C(N)=NC=NC=2N1C1OCC(CO)C1O KQLDDLUWUFBQHP-UHFFFAOYSA-N 0.000 description 3
- 229920000858 Cyclodextrin Polymers 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000001133 acceleration Effects 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- OFEZSBMBBKLLBJ-BAJZRUMYSA-N cordycepin Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)C[C@H]1O OFEZSBMBBKLLBJ-BAJZRUMYSA-N 0.000 description 3
- 239000007919 dispersible tablet Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000007938 effervescent tablet Substances 0.000 description 3
- 239000002662 enteric coated tablet Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 239000006191 orally-disintegrating tablet Substances 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 241000190633 Cordyceps Species 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 229920001100 Polydextrose Polymers 0.000 description 2
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 2
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 229940105329 carboxymethylcellulose Drugs 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229960001855 mannitol Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000001259 polydextrose Substances 0.000 description 2
- 235000013856 polydextrose Nutrition 0.000 description 2
- 229940035035 polydextrose Drugs 0.000 description 2
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 2
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 239000004384 Neotame Substances 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940030275 epigallocatechin gallate Drugs 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 210000001624 hip Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229960004903 invert sugar Drugs 0.000 description 1
- 239000000905 isomalt Substances 0.000 description 1
- 235000010439 isomalt Nutrition 0.000 description 1
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000019412 neotame Nutrition 0.000 description 1
- HLIAVLHNDJUHFG-HOTGVXAUSA-N neotame Chemical compound CC(C)(C)CCN[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 HLIAVLHNDJUHFG-HOTGVXAUSA-N 0.000 description 1
- 108010070257 neotame Proteins 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000008621 organismal health Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 229920000157 polyfructose Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 229940080350 sodium stearate Drugs 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 239000007939 sustained release tablet Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/066—Clavicipitaceae
- A61K36/068—Cordyceps
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Communicable Diseases (AREA)
- Botany (AREA)
- Polymers & Plastics (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Alternative & Traditional Medicine (AREA)
Abstract
The invention provides a composition of EGCG and cordyceps militaris extract, wherein 1000 g of cordyceps militaris and 300 g of EGCG are obtained by concentrating water extract of cordyceps militaris until the baume degree reaches 25-35 Be, mixing with EGCG, stirring at 45 ℃ for 30min, evaporating water at 45 ℃ by a rotary evaporator, drying and crushing; according to the invention, through specific amounts of cordyceps militaris and EGCG, concentrated solution of the cordyceps militaris water extract is creatively mixed with the EGCG at a specific Baume degree, and hydroxyl and ester groups in the EGCG are chemically bonded with the cordyceps militaris extract in a blending state at a specific temperature to form strong intermolecular van der Waals force, so that the cordyceps militaris water extract has good pharmaceutical stability; and the EGCG and the cordyceps militaris extract have pharmacological synergistic effects, and particularly have good pharmacological synergistic effects in the aspects of resisting tumors, protecting the nervous system, protecting cardiovascular and cerebrovascular vessels, resisting viruses, resisting bacteria, regulating immunity, resisting free radical damage, resisting oxidation, resisting oxidative stress, resisting thrombosis, resisting arteriosclerosis, resisting inflammation and the like.
Description
The invention relates to a health product composition and a preparation method thereof, in particular to an EGCG and cordyceps militaris extract, and a preparation method and application thereof. The health product composition provided by the invention comprises but is not limited to medicines, health nutriments, medical foods, health foods or functional foods, common foods and the like.
EGCG, epigallocatechin gallate, of the following structural formula,
EGCG is a natural compound extracted and separated from green tea, is easy to absorb moisture, is the most efficient active monomer component in tea polyphenol, has good safety and wide physiological activity, and researches show that the EGCG has the effects of resisting tumors, protecting the nervous system, resisting vascular proliferation, protecting cardiovascular and cerebrovascular vessels, resisting viruses, bacteria, regulating immunity, resisting free radical damage, resisting oxidation, resisting oxidative stress, resisting thrombosis, resisting arteriosclerosis and resisting inflammation, and is very important for human health.
However, EGCG has poor stability and is easily affected by factors such as temperature, water, pH and the like, particularly, when EGCG is stored in a liquid environment for 7 days, the hydrolysis/degradation rate of EGCG reaches over 17%, and even in a solid state, although the stability is relatively improved, EGCG is sensitive to temperature, gradually degrades in a hot environment, seriously affects the product quality and the development of EGCG preparations/products, and seriously adversely affects the preparation, storage, circulation and the like of products.
The improvement of the stability of the EGCG is important for the application of the EGCG, the improvement of the product quality and the guarantee of the health curative effect, and is also an important research subject of the EGCG.
Cordyceps militaris, also known as cordyceps militaris, cordyceps militaris and the like, has few natural resources distributed worldwide; the traditional Chinese medicine considers that the cordyceps militaris enters the lung and kidney two channels, can tonify lung yin and kidney yang, is mainly used for treating weakness after illness, chronic cough weakness, cough with phlegm and blood, waist and knee soreness, spontaneous perspiration and night sweat, immunity regulation and the like, and is the only traditional Chinese medicine capable of balancing and regulating yin and yang.
Especially, the cordyceps militaris has good effects of resisting tumors, viruses and inflammation, regulating immunity and protecting health of organisms. Cordycepin and cordyceps polysaccharide are main functional components of cordyceps militaris, and the cordycepin, namely 3-deoxyadenosine (3-deoxyadenosine), is a nucleic acid derivative containing nitrogen glycoside and has potential therapeutic effect on various diseases; cordycepin and cordyceps polysaccharide are water-soluble, however, the stability of the effective components in cordyceps militaris is poor, the preparation, the storage and the market circulation of the product are not facilitated, and the quality stability of the product is seriously influenced.
The cordyceps militaris is a natural compound treasury, the CGCG is a natural monomer compound and has poor stability, and researches show that the water extract of the cordyceps militaris and the EGCG have excellent pharmacological synergistic effect; disadvantageously, however, the presence of various compounds of the aqueous extract of cordyceps militaris has an adverse effect on the stability of its functional ingredients.
The invention aims to provide a stable composition of cordyceps militaris extract and EGCG, which not only meets the requirement that the water extract of cordyceps militaris and EGCG have good pharmacological synergistic effect, but also has good stability, and ensures the quality of products.
The invention provides a composition of EGCG and cordyceps militaris extract, and the specific technical scheme is as follows:
preparing materials: 1000 g of cordyceps militaris and 300 g of EGCG;
the preparation method comprises the following steps: selecting cordyceps militaris with a formula amount, removing impurities, cleaning, draining, slicing or properly crushing, adding 10-15 times of water by weight, stirring, heating to 80-100 ℃, extracting for 15-30 min, filtering to obtain filtrate, extracting filter residue for 10-15 min by using 10-15 times of hot water with the temperature of 90-100 ℃ according to needs, filtering to obtain filtrate, combining and collecting the two filtrates, and further concentrating the filtrate to enable the baume degree of the concentrated solution to reach 25-35 Be;
mixing the Cordyceps militaris concentrate with EGCG of a prescribed amount, mixing and stirring at 45 deg.C for 30min, placing in a rotary evaporator, evaporating at 45 deg.C to remove water, drying, and pulverizing.
The composition of the EGCG and the cordyceps militaris extract is a solid dispersion of the EGCG and the cordyceps militaris extract, and is characterized in that specific amounts of the cordyceps militaris and the EGCG are creatively mixed and dispersed with concentrated solution of the cordyceps militaris water extract at specific Baume concentration and the EGCG at specific temperature, the specific Baume concentration is a blending body of the cordyceps militaris extract and water, and hydroxyl and ester groups in the EGCG and the cordyceps militaris extract can be chemically bonded and valence combined in the blending body to finally form a stable and good solid dispersion of the EGCG and the cordyceps militaris extract.
The solid dispersion composition of the EGCG and the cordyceps militaris extract has the following two advantages:
1. the stability of EGCG is improved: the composition and the preparation method can uniformly disperse the EGCG and the cordyceps militaris extract in a liquid blending body, and the solid dispersion obtained by drying is highly dispersed solid powder or particles. The EGCG is a polyhydroxy substance, and under the blending and dispersing state, hydroxyl and ester groups in the EGCG are chemically bonded with the cordyceps militaris extract in the blending state to form stronger intermolecular van der Waals force, so that the stability of the EGCG is improved, and the EGCG has good pharmaceutical stability.
2. The solid dispersion does not contain other auxiliary materials, only the solid dispersion is formed by mixing the cordyceps militaris extract and the EGCG, the content and the titer of active ingredients are not changed, and the cordyceps militaris extract and the EGCG have pharmacological synergistic action; especially has good pharmacological synergistic effect in resisting tumor, protecting nervous system, resisting blood vessel hyperplasia, protecting cardiovascular and cerebrovascular, resisting virus, resisting bacteria, regulating immunity, resisting free radical damage, resisting oxidation, resisting oxidative stress, resisting thrombosis, resisting arteriosclerosis and resisting inflammation.
Furthermore, the invention also provides application of the solid dispersion of the EGCG and the cordyceps militaris extract in preparation of preparation compositions with different dosage forms.
The present invention provides that the solid dispersion of EGCG and cordyceps militaris extract according to the present invention can be administered by any suitable route, but typically by the oral route. For such applications, the solid dispersion of EGCG and cordyceps militaris extract may be prepared into any pharmaceutically acceptable dosage form by adding a suitable pharmaceutical carrier, however, the exact form of the composition naturally depends on the form of administration.
Different compound medicinal preparations can be prepared by using corresponding medicinal carriers or auxiliary materials and adopting different preparation processes. It should be understood that the compound preparation refers to a preparation prepared by taking the solid dispersion of EGCG and cordyceps militaris extract as a pharmaceutically active ingredient, and can be any pharmaceutically acceptable dosage form, preferably oral preparations, such as granules, powder, dry suspension, tablets (including dispersible tablets, enteric-coated tablets, chewable tablets, orally disintegrating tablets, effervescent tablets, and the like), hard capsules (including enteric-coated capsules), pills, micro-pills (including enteric-coated pellets), dropping pills, dry syrup, powder, oral solutions, oral suspensions, and oral quick-release or sustained-release or controlled-release dosage forms, and the like; or the preparation can be the quick release, sustained release, controlled release and other preparations of the above various preparations, such as oral dispersible tablets, sustained release capsules, enteric-coated tablets, effervescent tablets, orally disintegrating tablets, special-shaped tablets, effervescent granules and the like. In particular, the compound is prepared according to the method known in the field, and is preferably used for preparing oral solutions, tablets (including dispersible tablets, sustained-release tablets, enteric-coated tablets, effervescent tablets, orally disintegrating tablets and deformed tablets) and capsules (including gastric-coated, enteric-coated and sustained-release capsules) used in pharmaceutics.
The active ingredients of the pharmaceutical combination may generally be administered in the form of a solid dispersion of EGCG and cordyceps militaris extract, but preferably in the form of a pharmaceutical composition. The medicinal composition comprises solid dispersion of EGCG and cordyceps militaris extract, and one or more pharmaceutically acceptable carriers or excipients. These carriers must be acceptable, i.e., compatible with the other ingredients of the formulation, and non-toxic to the recipient thereof; the pharmaceutical composition of the invention can be prepared into different pharmaceutical dosage forms by using corresponding and different pharmaceutical carriers and preparation processes. It will be understood by those skilled in the art that these pharmaceutical carriers are selected for ease of manufacturing, processing into various dosage forms, ensuring the safety, efficacy and stability of the drug, and according to the physical and chemical properties of the different dosage forms and the drug itself. The choice of a pharmaceutically acceptable carrier is well known and obvious to those skilled in the art of the present invention.
It is understood that for oral agents, pharmaceutical carriers, such as fructo-oligosaccharide, microcrystalline cellulose, mannitol, non-dairy creamer, lactose, pregelatinized starch, dextrin, cyclodextrin, hydroxypropyl- β -cyclodextrin, calcium phosphate, calcium hydrogen phosphate, hydroxypropyl methylcellulose, sucrose, dextran, poloxamer, sodium chloride, xylitol, sorbitol, fructose, glucose, xylo-oligosaccharide, polydextrose, oligomannose, solid polyethylene glycols (e.g., polyethylene glycol-4000, polyethylene glycol-12000, polyethylene glycol-6000, polyethylene glycol-2000, etc.), liquid polyethylene glycols (e.g., polyethylene glycol-400), resistant dextrins, water, propylene glycol, glycerin, vegetable oils, cyclodextrins, hydroxypropyl- β -cyclodextrin and derivatives thereof, coffee, milk powder, vegetable protein powder, etc., for oral solid formulations, such as povidone, methylcellulose, carboxymethylcellulose, hydroxypropyl methylcellulose, pregelatinized starch, sodium carboxymethylcellulose, sodium alginate, sodium stearate.
In the application of the invention, the composition refers to a solid dispersion of the extract of EGCG and cordyceps militaris, or a composition comprising the solid dispersion of the extract of EGCG and cordyceps militaris, such as a mixture formed by adding other preparation auxiliary materials and physiologically/pharmaceutically acceptable carriers or excipients according to needs, and the purpose of the pharmaceutical composition is to facilitate the application, carrying and storage of the medicament; as used herein, "administering" means administering a solid dispersion or composition of EGCG and Cordyceps militaris extract of the present invention to an organism (including a patient or a healthy person) for the purpose of preventing or treating a disease.
Detailed description of the inventionin the practice of the present invention, various embodiments and modifications will be apparent to and can be readily made by those of ordinary skill in the art without departing from the scope and spirit of the invention. The following examples are intended to further specifically illustrate the application and the like of the present invention, but are not intended to limit the present invention.
Example 1, solid dispersion of EGCG and cordyceps militaris extract and preparation thereof.
Preparing materials: 1000 g of cordyceps militaris and 300 g of EGCG;
the preparation method comprises the following steps: selecting the formula amount of cordyceps militaris, removing impurities, cleaning, draining, slicing or properly crushing, adding 15 weight parts of water, stirring, heating to 95 ℃, leaching for 20min, filtering to obtain filtrate, leaching filter residue for 15min by using 10 weight parts of 100 ℃ hot water, filtering to obtain filtrate, combining and collecting the two filtrates, and further concentrating the filtrate to enable the baume degree of the concentrated solution to reach 30 DEG Be;
mixing the Cordyceps militaris concentrate with EGCG of a prescribed amount, mixing and stirring at 45 deg.C for 30min, placing in a rotary evaporator, evaporating at 45 deg.C to remove water, drying, and pulverizing.
Example 2, solid preparation of solid dispersion of EGCG and cordyceps militaris extract and preparation thereof.
The prescription amount comprises the following components in percentage by weight:
2 to 10 percent of solid dispersion of the EGCG and the cordyceps militaris extract, preferably 6 percent,
90-98% of granule auxiliary materials, preferably 94% of fructose or 94% of xylitol;
wherein the granule adjuvant comprises one or more of xylitol, fructose, polyfructose, xylooligosaccharide, polydextrose, mannitol, sucrose, invert sugar (equal amount of mixture of glucose and fructose), glucose, resistant dextrin, sorbitol, maltose, isomalt, oligomannose, solid polyethylene glycol (such as polyethylene glycol-4000, polyethylene glycol-12000, polyethylene glycol-6000, polyethylene glycol-2000, etc.), dextrin, cyclodextrin, maltodextrin, hydroxypropyl- β -cyclodextrin, microcrystalline cellulose, carboxymethyl cellulose, hydroxypropyl methyl cellulose, pregelatinized starch, starch sugar, lactose, vegetable fat powder, milk powder, vegetable protein powder, coffee, sodium carboxymethyl starch, proteoglycan, sucralose, aspartame, acesulfame potassium, stachyose, neotame, stevioside, and most preferably fructose or xylitol;
the preparation method comprises the following steps: respectively sieving the solid dispersion of the EGCG and the cordyceps militaris extract prepared in the example 1 and the granule auxiliary materials with a 80-mesh sieve, preferably 100-mesh sieve, weighing according to the prescription amount, uniformly mixing the solid dispersion of the EGCG and the cordyceps militaris extract and the granule auxiliary materials, performing wet granulation by using a 75% ethanol solution, drying at 45-70 ℃, finishing granules,to obtain the granular formulation,packaging and inspecting to obtain the final product.
Further, the granules can be compressed into tablets through a tabletting process, or the granules can be filled into hollow capsule shells to obtain capsules.
Example 3, solid preparation of solid dispersion of EGCG and cordyceps militaris extract and preparation thereof.
The prescription amount comprises the following components in percentage by weight:
6 percent of solid dispersion of EGCG and cordyceps militaris extract,
94% of fructo-oligosaccharide;
the preparation method comprises the following steps: and (2) respectively sieving the EGCG prepared in the example 1, the solid dispersion of the cordyceps militaris extract and fructo-oligosaccharide with a 80-mesh sieve, preferably 100-mesh sieve, weighing according to the prescription amount, uniformly mixing the EGCG and the solid dispersion of the cordyceps militaris extract with the fructo-oligosaccharide, performing wet granulation by using a 75% ethanol solution, drying at 45-70 ℃, granulating to obtain granules, packaging and inspecting to obtain the product.
Further, the granules can be compressed into tablets through a tabletting process, or the granules can be filled into hollow capsule shells to obtain capsules.
Example 4, stability study of solid dispersion of EGCG and cordyceps militaris extracts.
The solid dispersions of the EGCG and the cordyceps militaris extract in example 1 are respectively taken, pure EGCG powder is taken as a blank reference, each sample is sampled for 8 times (n =8), the detected data result is averaged, the sample is placed for 2 months through a stability acceleration test (at 40 ℃ and under the condition of 75% humidity), the sample is sampled and detected, the content of the EGCG in each sample is detected by adopting an HPLC method, the result is compared with 0 day, the content reduction value of the EGCG at the time point of 2 months is obtained, and the data is processed by statistical software.
The detection method comprises the following steps: the content is determined by high performance liquid chromatography, 0.1 phosphoric acid and acetonitrile are used as mobile phases, the sample amount is 20 mu L, the column temperature is 28 ℃, the detection wavelength is 273nm, and the retention time is more than 7 min.
The test results are shown in table 1 below.
Table 1.
And (4) conclusion: the solid dispersion of the EGCG and the cordyceps militaris extract can obviously improve the stability of the EGCG, has very obvious difference, and p is less than 0.001.
Example 5, stability study of solid formulation of solid dispersion of EGCG and cordyceps militaris extract.
The solid preparation of the solid dispersion of the EGCG and the cordyceps militaris extract in example 3 is taken respectively, pure EGCG powder is taken as a blank reference, 8 samples (n =8) are taken from each sample, the detected data result is averaged, the sample is placed for 2 months through a stability acceleration test (at 40 ℃ and under the condition of humidity of 75%), the sample is taken for detection, the content of the EGCG in each sample is detected by an HPLC method, the result is compared with 0 day, the content reduction value of the EGCG at the time point of 2 months is obtained, and the data is processed by statistical software.
The detection method comprises the following steps: the content is determined by high performance liquid chromatography, 0.1 phosphoric acid and acetonitrile are used as mobile phases, the sample amount is 20 mu L, the column temperature is 28 ℃, the detection wavelength is 273nm, and the retention time is more than 7 min.
The results of the tests are shown in Table 2 below.
Table 2.
And (4) conclusion: the solid preparation of the solid dispersion of the EGCG and the cordyceps militaris extract can obviously improve the stability of the EGCG, has very obvious difference, and p is less than 0.001.
Example 6, stability study of solid dispersion of EGCG and cordyceps militaris extracts.
The solid dispersions of the EGCG and the Cordyceps militaris extract in example 1 are taken respectively, and compared with the solid dispersion A and the solid dispersion B respectively for the stability. The preparation method of the solid dispersion A and the solid dispersion B comprises the following steps:
solid dispersion A: taking 1000 g of cordyceps militaris and 350 g of EGCG, and taking the solid dispersion prepared by the preparation method in the embodiment 1 as a solid dispersion A of a contrast study;
solid dispersion B: the solid dispersion prepared according to the preparation method in the example 1 and 1000 g of cordyceps militaris and 250 g of EGCG was taken as the solid dispersion B of the comparative study.
Comparison method: 8 samples (n =8) are taken from each sample, the detected data result is averaged, the sample is placed for 2 months through a stability acceleration test (at 40 ℃ and under the condition of 75% humidity), the sample is sampled and detected, the content of the EGCG in each sample is detected by adopting an HPLC method, the result is compared with 0 day, the content reduction value of the EGCG at the time point of 2 months is obtained, and the data is processed by statistical software.
The detection method comprises the following steps: the content is determined by high performance liquid chromatography, 0.1 phosphoric acid and acetonitrile are used as mobile phases, the sample amount is 20 mu L, the column temperature is 28 ℃, the detection wavelength is 273nm, and the retention time is more than 7 min.
The test results are shown in Table 3 below.
Table 3.
And (4) conclusion: compared with the solid dispersion A and the solid dispersion B, the solid dispersion of the EGCG and the cordyceps militaris extract can obviously improve the stability of the EGCG, has obvious difference, and p is less than 0.01.
The solid dispersion prepared by the specific preparation method has the specific ratio of 1000 g of cordyceps militaris to 300 g of EGCG, and the stability of EGCG is remarkably improved.
The solid dispersion of the EGCG and the cordyceps militaris extract described in the embodiment 7 and the embodiment 1, and the solid preparation of the solid dispersion of the EGCG and the cordyceps militaris extract described in the embodiment 2 are applied to the following aspects:
the application in preparing medicinal preparation for preventing and treating tumor, protecting nervous system, resisting blood vessel hyperplasia, protecting cardiovascular and cerebrovascular, resisting virus, resisting bacteria, regulating immunity, resisting free radical damage, resisting oxidation, resisting oxidative stress, resisting thrombosis, resisting arteriosclerosis and resisting inflammation.
Claims (5)
1. A composition of EGCG and cordyceps militaris extract is characterized in that:
preparing materials: 1000 g of cordyceps militaris and 300 g of EGCG;
the preparation method comprises the following steps: selecting cordyceps militaris with a formula amount, removing impurities, cleaning, draining, slicing or properly crushing, adding 10-15 times of water by weight, stirring, heating to 80-100 ℃, extracting for 15-30 min, filtering to obtain filtrate, extracting filter residue for 10-15 min by using 10-15 times of hot water with the temperature of 90-100 ℃, filtering to obtain filtrate, combining and collecting the two filtrates, and further concentrating the filtrate to enable the baume degree of a concentrated solution to reach 25-35 Be;
mixing the Cordyceps militaris concentrate with EGCG of a prescribed amount, mixing and stirring at 45 deg.C for 30min, placing in a rotary evaporator, evaporating at 45 deg.C to remove water, drying, and pulverizing.
2. A solid dispersion of EGCG and Cordyceps militaris extract is characterized in that:
preparing materials: 1000 g of cordyceps militaris and 300 g of EGCG;
the preparation method comprises the following steps: selecting the formula amount of cordyceps militaris, removing impurities, cleaning, draining, slicing or properly crushing, adding 15 weight parts of water, stirring, heating to 95 ℃, leaching for 20min, filtering to obtain filtrate, leaching filter residue for 15min by using 10 weight parts of 100 ℃ hot water, filtering to obtain filtrate, combining and collecting the two filtrates, and further concentrating the filtrate to enable the baume degree of the concentrated solution to reach 30 DEG Be;
mixing the Cordyceps militaris concentrate with EGCG of a prescribed amount, mixing and stirring at 45 deg.C for 30min, placing in a rotary evaporator, evaporating at 45 deg.C to remove water, drying, and pulverizing.
3. A solid preparation of solid dispersion of EGCG and cordyceps militaris extract comprises the following components in percentage by weight:
the solid dispersion of EGCG and Cordyceps militaris extract of claim 2, 6%,
94% of fructo-oligosaccharide;
the preparation method comprises the following steps: respectively sieving the solid dispersion of the EGCG and the cordyceps militaris extract and the fructo-oligosaccharide with a 80-mesh sieve, weighing according to the formula, uniformly mixing the solid dispersion of the EGCG and the cordyceps militaris extract and the fructo-oligosaccharide, carrying out wet granulation by using a 75% ethanol solution, drying at 45-70 ℃, and finishing granules to obtain granules.
4. The solid preparation of solid dispersion of EGCG and Cordyceps militaris extract as claimed in claim 3, wherein the solid preparation is prepared from EGCG and Cordyceps militaris extract
The granules are compressed into tablets by a tabletting process, or the granules are filled into hollow capsule shells to obtain capsules.
5. The use of the composition of EGCG and cordyceps militaris extract as claimed in claim 1 in:
the application in preparing medicinal preparation for preventing and treating tumor, protecting nervous system, resisting blood vessel hyperplasia, protecting cardiovascular and cerebrovascular, resisting virus, resisting bacteria, regulating immunity, resisting free radical damage, resisting oxidation, resisting oxidative stress, resisting thrombosis, resisting arteriosclerosis and resisting inflammation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010369198.6A CN111297918A (en) | 2020-05-04 | 2020-05-04 | Composition of EGCG and cordyceps militaris extract and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010369198.6A CN111297918A (en) | 2020-05-04 | 2020-05-04 | Composition of EGCG and cordyceps militaris extract and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111297918A true CN111297918A (en) | 2020-06-19 |
Family
ID=71146423
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010369198.6A Pending CN111297918A (en) | 2020-05-04 | 2020-05-04 | Composition of EGCG and cordyceps militaris extract and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111297918A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114601009A (en) * | 2022-04-06 | 2022-06-10 | 常熟理工学院 | Silkworm chrysalis cordyceps sinensis tablet candy and preparation method thereof |
| CN116970290A (en) * | 2023-06-28 | 2023-10-31 | 安发（福建）生物科技有限公司 | Cordyceps militaris pigment extract and preparation method and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104719910A (en) * | 2015-04-19 | 2015-06-24 | 福州乾正药业有限公司 | Solid dispersion combination of EGCG (epigallocatechin gallate) with thermal stability and preparation method of solid dispersion combination and application in preparation of solid dispersion combination |
| CN104922164A (en) * | 2014-12-12 | 2015-09-23 | 中国医科大学 | Composite medicine preparation for treating alzheimer disease |
| CN105614869A (en) * | 2016-02-14 | 2016-06-01 | 王保红 | Composition containing Cordyceps militaris and preparation method and application thereof |
-
2020
- 2020-05-04 CN CN202010369198.6A patent/CN111297918A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104922164A (en) * | 2014-12-12 | 2015-09-23 | 中国医科大学 | Composite medicine preparation for treating alzheimer disease |
| CN104719910A (en) * | 2015-04-19 | 2015-06-24 | 福州乾正药业有限公司 | Solid dispersion combination of EGCG (epigallocatechin gallate) with thermal stability and preparation method of solid dispersion combination and application in preparation of solid dispersion combination |
| CN105614869A (en) * | 2016-02-14 | 2016-06-01 | 王保红 | Composition containing Cordyceps militaris and preparation method and application thereof |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114601009A (en) * | 2022-04-06 | 2022-06-10 | 常熟理工学院 | Silkworm chrysalis cordyceps sinensis tablet candy and preparation method thereof |
| CN116970290A (en) * | 2023-06-28 | 2023-10-31 | 安发（福建）生物科技有限公司 | Cordyceps militaris pigment extract and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3135300B1 (en) | Disintegrating particle composition including microfibrous cellulose | |
| CN104719910B (en) | EGCG solid dispersion compositions with heat endurance and its preparation method and application | |
| EP2979697A1 (en) | Oral administration preparation with masked bitterness of silodosin | |
| CN104922145A (en) | Composition of gamma-aminobutyric acid and chitosan oligosaccharide, as well as preparation method and applications of composition | |
| EP3626272B1 (en) | Composition for disintegrating tablets containing microfibrous cellulose and active ingredient | |
| US11786506B2 (en) | Transmucosal psychoactive alkaloid composition and preparation thereof | |
| CN111297918A (en) | Composition of EGCG and cordyceps militaris extract and preparation method and application thereof | |
| CN104721230A (en) | Composite of milk basic protein and milk mineral, preparation method thereof and application | |
| CZ292832B6 (en) | Process for preparing silymarin exhibiting increased solubility | |
| EP3225256B1 (en) | Disintegrative particle composition including pulverized lactose or granulated lactose | |
| CZ14296A3 (en) | Process for preparing flavone-ligand preparations with improved release and resorbing capacity, in such a manner obtained agents and their use for preparing medicaments | |
| CN104922143A (en) | EGCG (epigallocatechin gallate) and chitosan oligosaccharide composition as well as preparation method and application thereof | |
| KR102095536B1 (en) | Oral formulation for improved dissolution rate and disintegrability of herbal extract | |
| CN116942743A (en) | Preparation method of Ganmaoqing tablet and product thereof | |
| CN1762341B (en) | Salvianolic acid compound for treating cardiovascular and cerebrovascular disease and liver disease, and application thereof | |
| CN109589323A (en) | Nervonic acid and the solid dispersion composition of EGCG and its preparation method and application | |
| CN102614182A (en) | Solid preparation of compound ammonia phenol renin medicine composition liposome | |
| CN104825441A (en) | EGCG and gamma-aminobutyric acid composition, and preparation method and applications thereof | |
| CN102370677A (en) | Three-flavor sandalwood preparation and preparation method thereof | |
| CN104840800A (en) | Composition of bamboo leaf flavonoid and gamma-aminobutyric acid as well as preparation method and applications thereof | |
| CN101108224A (en) | Plants natural base extractive and formulated product and use thereof | |
| TWI644688B (en) | Method for producing orally disintegrating lozenge containing disintegrating particle composition | |
| CN112353802A (en) | Vonola fumarate taste masking composition and application thereof | |
| CN102247331B (en) | Cefadroxil chewable tablets and preparation method thereof | |
| CN104739776A (en) | Solid dispersion composition of levocarnitine as well as preparation method and medical application of solid dispersion composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20200619 |
|
| WD01 | Invention patent application deemed withdrawn after publication |